Pfizer(US:PFE) Seeking Alpha·2026-01-12 20:16Core Insights - Pfizer had a strong financial performance in 2025, achieving three consecutive quarters of beating both revenue and profitability expectations [2] - The company successfully reduced operational expenses by $5.6 billion between 2024 and 2025, demonstrating effective execution [2] - Certain uncertainties that previously affected Pfizer's valuation multiples, such as tariffs and COVID-related profitability concerns, have been largely resolved [3] Financial Performance - Pfizer reported a good year in 2025 with improved financial metrics [2] - The company achieved consecutive earnings beats in revenue and profitability for four quarters in 2024 and three quarters in 2025 [2] - Operational expenses were significantly reduced, indicating strong cost management [2] Market Conditions - The resolution of tariff issues has positively impacted the entire industry, including Pfizer [3] - Specific concerns related to COVID's impact on profitability for Pfizer have been addressed, contributing to a more stable outlook [3]